Gilead moving forward with long-acting HIV treatments

Gilead said its first-in-class capsid inhibitor significantly reduced viral loads in HIV patients, representing in vivo proof of concept for a therapy that could provide a long-acting treatment option for treatment-experienced people living with multidrug resistant HIV. The company also entered a deal with Durect to develop a sustained-release product for HIV.

Although Gilead Sciences Inc. (NASDAQ:GILD) said the Phase Ib study results for GS-6207 support advancing the capsid inhibitor into the next development phase, spokesperson Brian Plummer declined to give a specific timeline. He said the company believes GS-6207 "could be part of long-acting combination therapy for a broad patient population."...